Researchers investigating the role of progranulin in cancer progression have previously identified the signaling receptor EphA2 as critical in tumor establishment and a potential target to enhance the effectiveness of chemotherapy. While the exact molecular mechanisms of action are still not well understood, the growth factor progranulin is known to be involved in several human pathologies, including frontotemporal dementia (FTD), immune response and cancer. A new study identifies the protein FAM120A as a critical effector in the progranulin/EphA2 tumorigenic axis.
Discover Recifes.net
This story is part of Recifes international coverage. Explore the platform and follow us — new English social channels come next.
